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Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases.
Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target.
In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating
the clinical eﬃcacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review
addresses frequently used EGFR inhibitors, summarizes clinical eﬃcacy data of these new therapeutic agents, and discusses their
associated toxicity and management.
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1.Introduction
Epidermal growth factor receptor (EGFR), a member of the
ErbB family of receptor tyrosine kinases, is a cell surface
molecule whose activation leads to an intracellular signaling
cascade aﬀecting invasion, apoptosis, and angiogenesis [1,
2]. Members of the EFGR family receptors (erb1/EFGR,
erb2/HER2, erb3/HER3, and erb4/HER4) are composed of
extracellular ligand binding domains. When ligands bind
to these domains, receptor dimerization and autophos-
phorylation of intracellular tyrosine kinase domains occur.
Autophosphorylation activates the downstream signaling
pathways ras, raf, mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (Pl3K), Akt, and the signal
transductionandactivatoroftranscription(STAT)pathways.
This downstream signaling leads to activation of cell growth,
proliferation,andsurvivalofcells[3,4].BindingoftheEGFR
by inhibitors leads to a disruption in proliferation resulting
in apoptosis. Immunological eﬀects, such as cell-dependent
cytotoxicity (CDC) and antibody-dependent cell-mediated
cytotoxicity (ADCC), also contribute to their mechanism of
action [5].
Drugs targeting EGFR in malignancies were initially
developed in the 1980s, which lead to the development of
anti-EGFRmonoclonalantibodiesandsmallmoleculeEGFR
tyrosine kinase inhibitors (TKIs) [6–9]. EGFR is overex-
pressed in many solid tumors and this over expression corre-
lates to advanced stage and a worse prognosis [10]. In the last
few years, numerous clinical trials have proven the clinical
eﬃcacy of EGFR-targeted therapies in the management of
several cancers, including breast, colon, pancreas, head and
neck, renal, gastrointestinal stromal tumors (GISTs), and
lung carcinomas. Since these agents are now commonly
used, clinical presentation of associated toxicities and their
management are important to recognize. Therefore, this
review discusses commonly used EFGR inhibitors currently
approved by the US Food and Drug Administration (FDA).
A summary of clinical data in support of these agents
and commonly encountered toxicities and management are
discussed.
2. Anti-EGFRAgents Efﬁcacy
2.1. Erlotinib. Erlotinib is an oral agent that reversibly
binds to the intracellular tyrosine kinase domain of the
HER1/EGFR thus blocking phosphorylation and inhibiting
signal transduction [11]. Initially studied in nonsmall cell
lung cancer (NSCLC), phase II data showed a response rate
(RR) of 12% in patients previously treated with platinum-
based chemotherapy [12, 13]. The National Cancer Institute2 Journal of Oncology
of Canada Clinical Trials Group (NCICCTG) then developed
a phase III trial comparing erlotinib to placebo in patients
with advanced NSCLC who had prior failure of ﬁrst- or
second-line chemotherapy. This study showed that erlotinib
when compared to placebo had a higher overall (O)RR,
median duration of response, progression-free survival
(PFS), and overall survival (OS) (Table 1). There was also a
greater reduction in cancer-related pain, cough, and dyspnea
as well as improvement in physical function in those treated
with erlotinib [14]. As a result, erlotinib is a useful treatment
option presently utilized in the management of NSCLC.
In another large phase III randomized trial of previously
untreated advanced NSCLC, the combination of carboplatin
and paclitaxel with or without erlotinib was evaluated. The
results were not as favorable and showed no diﬀerence in
ORRorOS[11].EGFRgenemutationsarebeinginvestigated
as a predictor of eﬃcacy with erlotinib in NSCLC. Recently
presented at the American Society of Clinical Oncology
(ASCO) Annual Meeting, a phase II trial of erlotinib in
previously untreated NSCLC patients with mutations of the
tyrosine kinase domain of EGFR was evaluated. In this trial,
37 of 297 tumors screened had mutations in the tyrosine
kinase domain (25 with exon 19 deletion, 11 with L858R
mutation). Responses occurred in 100% of exon 19 deletions
and in 75% of those with the L858R mutation [15].
HER1/EGFRs are also overexpressed in pancreatic
tumors conferring a worse prognosis. This led to an NCIC
trial comparing gemcitabine in combination with erlotinib
or placebo in patients with locally advanced or metastatic
pancreatic adenocarcinomas. This trial showed a minimal
but statistically signiﬁcant increase in OS favoring the
gemcitabine/erlotinib combination. Although statistically
signiﬁcant, the absolute increase in median survival was only
2w e e k s[ 16].
2.2. Geﬁtinib. Geﬁtinib, an orally bioavailable EGFR TKI,
was the ﬁrst targeted drug to be approved for NSCLC. The
Iressa Dose Evaluation in Adjuvant Lung Cancer (IDEAL1
and IDEAL2) trials were phase II nonrandomized studies
investigating the eﬃcacy of geﬁtinib monotherapy in NSCLC
patients previously treated with a platinum agent [17, 18].
Based on objective responses, stable disease, and symp-
tomaticimprovement,geﬁtinibreceivedacceleratedapproval
by the FDA in 2003. In 2005, the Iressa Survival Evaluation
in Lung Cancer (ISEL) trial, a phase III randomized study,
evaluated geﬁtinib versus placebo in previously treated
NSCLC [19]. Although there was a signiﬁcantly higher
response rate seen with geﬁtinib, the study did not show a
signiﬁcant diﬀerence in OS. As a result, the FDA restricted
the use of geﬁtinib to patients enrolled in clinical trials or
deriving beneﬁt from ongoing treatment. Other randomized
phase III trials, assessing geﬁtinib given concurrently with
chemotherapy as well as geﬁtinib maintenance did not show
improvements in OS [20–22]. Recently, the 33rd European
Society for Medical Oncology Congress released results of
a large-scale randomized phase III trial (IRESSA Pan-Asia
study [IPASS]) [23]. In 1,217 patients, the study com-
pared geﬁtinib monotherapy to carboplatin/paclitaxel (C/P)
in chemonaive never- or light-exsmokers with advanced
NSCLC with adenocarcinoma histology (Table 2). Geﬁtinib
was superior in PFS, ORR, toxicity, and quality of life
(QOL) compared to combination chemotherapy. However,
OS and symptom improvement were similar between the
two groups. PFS was longer for geﬁtinib than C/P in EGFR
mutation positive patients and longer with C/P in mutation-
negative patients.
2.3. Cetuximab. Cetuximab is a chimeric monoclonal IgG1
antibody that binds to the EGFR subsequently blocking
phosphorylation of the receptor [24]. Cetuximab, initially
approved for the treatment of metastatic colon cancer,
has made a signiﬁcant diﬀerence in the management of
patients with this disease. A phase III trial comparing
cetuximab monotherapy to best supportive care (BSC)
showed improved OS and QOL in patients with colorectal
cancer who had previously failed or had contraindications
to ﬂuoropyrimidine-, irinotecan-, and oxaliplatin-based
therapies (Table 2)[ 25]. A subsequent randomized phase
III trial compared cetuximab monotherapy to cetuximab
plus irinotecan in refractory metastatic colorectal cancer
(mCRC). This study was reserved for patients who had
documented disease progression on a prestudy irinotecan
regimen. The combination therapy arm showed signiﬁcantly
improved ORR, median time to progression (TTP), and
disease control [26]. Another similar randomized phase
III trial evaluated irinotecan monotherapy to cetuximab
plus irinotecan in patients with mCRC previously failing
oxaliplatin and/or a ﬂuoropyrimidine who were irinotecan
na¨ ıve. The combination therapy arm yielded improved ORR,
PFS, and QOL, but similar OS to the cetuximab-only treated
patients. This lack of OS diﬀerence may have been due to
posttrial therapy since a large number of patients assigned to
irinotecan eventuallyreceivedcetuximab[27].Most recently,
the combination of irinotecan and 5-ﬂuorouracil (FOLFIRI)
with or without cetuximab in the ﬁrst-line treatment of
mCRC was evaluated. Cetuximab in combination with
FOLFIRI signiﬁcantly increased ORR and PFS [28].
The combination of EGFR and vascular endothelial
growth factor-(VEGF-) targeted agents was also evaluated
in a randomized phase III study of capecitabine/oxaliplatin
(CapOx) plus bevacizumab with or without cetuximab
in mCRC. Unfortunately, the combination chemother-
apy, bevacizumab, and cetuximab resulted in a signiﬁcant
decrease in PFS compared to bevacizumab and CapOx
a l o n ew i t hn od i ﬀerence in OS [29]. Therefore, it was
concluded that cetuximab and bevacizumab should not be
used concomitantly with chemotherapy.
At last year’s ASCO annual meeting, data revealed that
KRAS gene mutation conferred resistance to treatment with
cetuximab and panitunimab. In contrast, “wild-type” or
normal KRAS mutation status was found to be a predictive
marker for cetuximab and panitumumab eﬃcacy. In a ret-
rospective analysis of 5-ﬂuorouracil/leucovorin/oxaliplatin
(FOLFOX) in combination with cetuximab, KRAS wild-type
status was found to be associated with a signiﬁcantly higher
ORR and longer PFS when compared to mutant KRAS in
EGFR-positive patients [29]. Similarly, when EGFR-positive
patients with untreated mCRC were treated with FOLFIRIJournal of Oncology 3
Table 1: Selected clinical trials of erlotinib. NSCLC, Non-small cell lung cancer; OS, overall survival; ORR, overall response rate.
Malignancy Regimen Number of patients Results Comments
NSCLC Erlotinib vs.
placebo [14]
731pts
Stage IIIB/IV NSCLC
after failure with
ﬁrst-line or second-line
chemotherapy
Erlotinib:
ORR (8.9%)
OS (6.7mo)
Placebo:
ORR (<1%)
OS (4.7mo)
Signiﬁcant improvement in OS
(P<. 001)
NSCLC
Carboplatin,
Paclitaxel +/−
Erlotinib [11]
1059pts
Previously untreated
stage IIIB/IV NSCLC
Erolotinib:
ORR (21.5%)
OS (10.6mo)
Placebo:
ORR (19.3%)
OS (10.5mo)
No diﬀerence in ORR or OS with
the combination of Erlotinib and
chemotherapy
Pancreatic cancer
Gemcitibine,
Erlotinib vs.
placebo [15]
569pts
Unresectable, locally
advanced or metastatic
pancreatic cancer
Erlotinib:
OS (6.2mo)
Placebo:
OS (5.9mo)
One year survival was greater
with erlotinib plus gemcitabine
(23% vs. 17%; P = .023)
Table 2: Selected clinical trials of geﬁtinib. NSCLC, Non-small cell lung cancer; OS, overall survival; ORR, overall response rate; C/P,
carboplatin/paclitaxel; PFS, progression free survival; EGFR, e p i d e r m a lg r o w t hf a c t o rr e c e p t o r .
Malignancy Regimen Number of patients Results Comments
NSCLC Geﬁtinib vs.
placebo [19]
1692pts
Second-line or third-line
treatment for patients
with locally advanced or
metastatic NSCLC
Geﬁtinib:
OS (5.6mo)
Placebo:
OS (5.1mo)
No signiﬁcant
improvement in OS
(P = .087)
Subgroup analysis showed
signiﬁcantly longer survival
in never-smokers and Asian
patients
NSCLC
Geﬁtinib vs. Car-
boplatin/paclitaxel
(C/P) [23]
1,217pts
Previously untreated stage
IIIB/IV NSCLC, never- or
light ex-smokers,
adenocarcinoma histology
Geﬁtinib:
ORR (43%)
OS (18.6mo)
C/P:
ORR (32%)
OS (17.3mo)
P = .0001
No OS diﬀerence PFS
longer for geﬁtinib than
C/P in EFGR mutation
positive patients
(P<. 0001)
PFS longer with C/P in
mutation negative patients
(P<. 0001)
with or without cetuximab, KRAS mutational status was
predictive of response; wild-type KRAS was associated with
improved ORR and prolonged PFS. Based on these studies
as well as data with panitumumab, KRAS testing and
veriﬁcation of wild-type status are now required before
treatment with these agents in colorectal cancer [29–31].
EGFR is also upregulated in squamous cell carcinoma
(SCC) of the head and neck. The use of cetuximab to treat
this disease has signiﬁcantly beneﬁted these patients. Initial
phase II data revealed activity of single agent cetuximab in
recurrent and/or metastatic SCC of the head and neck in
those failing to respond to platinum-based therapy. As a
single agent, the RR was 13% with a disease control rate of
46% [32]. The combination of cetuximab with chemother-
apy has also been found to be eﬀective. Platinum-based
chemotherapy, ﬂuorouracil, with or without cetuximab as
ﬁrst-line treatment of metastatic or recurrent SCC of the
head and neck showed that the cetuximab combination
yielded a higher ORR and OS [33]. A similar phase III trial
was conducted addressing PFS with cisplatin monotherapy
versus cisplatin with cetuximab in patients with recurrent
and/or metastatic SCC of the head and neck. This included
patients with documented progression during prior cisplatin
therapy. This study did not show a signiﬁcant diﬀerence in
PFS or OS; however, there was a signiﬁcant diﬀerence in
RR favoring the cetuximab/cisplatin arm [34]. Cetuximab
withradiotherapyversusradiotherapyalonewasalsostudied
in a separate phase III trial. The addition of cetuximab to
radiotherapy signiﬁcantly prolonged PFS, median OS, and
duration of locoregional control in patients with locoregion-
ally advanced head and neck cancer [35].
In pancreatic adenocarcinoma, trials with cetuximab
have not shown signiﬁcant clinical beneﬁt. Cetuximab with
gemcitabine or gemcitabine alone was evaluated in a large
multi-institutional phase III trial in pancreatic adenocar-
cinoma. The addition of cetuximab did not signiﬁcantly
improve ORR, PFS, or OS [36–38].
At the plenary session of ASCO 2008, data was released
on the treatment of NSCLC with cetuximab in combination
with cisplatin/vinorelbine (CV) compared to CV alone. Only4 Journal of Oncology
patients with EGFR detectable by immunohistochemistry
(IHC) were randomized. Cetuximab plus CV demonstrated
an OS advantage. A modest survival beneﬁt of one-to-two
month(s) was seen depending on histology. This was the ﬁrst
trial to demonstrate an OS advantage of an EGFR-targeted
agent in combination with platinum-based chemotherapy in
NSCLC [39].
EGFR gene copy number detected by ﬂuorescent in situ
hybridization(FISH)hasbeenshowntobeusefulinselecting
NSCLC patients for treatment with cetuximab. Patients
with advanced-stage NSCLC were enrolled into a phase
II trial evaluating sequential or concurrent chemotherapy
(carboplatin plus paclitaxel) with cetuximab. The ORR,
disease control rate, PFS, and OS were signiﬁcantly higher
in the FISH-positive versus FISH-negative patients [40].
Further investigation on the accuracy of FISH-positive
EGFR status is needed to evaluate its prognostic value in
NSCLC.
2.4. Panitumumab. In contrast to cetuximab, panitumumab
is the ﬁrst fully human EGFR monoclonal antibody. It is an
immunoglobulin (Ig)G2 antibody that binds to the extracel-
lular portion of the EGFR thus inhibiting phosphorylation
and activation of the intracellular kinases [41]. Eﬃcacy
of panitumumab has been evaluated in EGFR-expressing
metastatic colorectal adenocarcinomas with disease progres-
sion following oxaliplatin, irinotecan, and ﬂuropyrimidine-
containing chemotherapy regimens. An initial phase II
multicenter trial included patients with progressive mCRC
treated with panitumumab monotherapy; patients were
stratiﬁed into two groups based on EGFR staining intensity.
As a single agent, panitumumab response and disease sta-
bilization were seen irrespective of EGFR staining intensity
[42]. This led to a phase III trial comparing panitumumab
monotherapy to BSC alone. Eﬃcacy was evaluated in
patients with 1% or greater EGFR tumor staining by IHC
and disease progression while on or within 6 months
of the most recent chemotherapy. Panitumumab yielded
a signiﬁcant reduction in PFS when compared to BSC;
however, there was no signiﬁcant diﬀerence in OS (Table 3)
[43]. Patients in the BSC arm were subsequently allowed to
crossover to the panitumumab arm if disease progression
was documented during the study. The crossover patient
population yielded comparable results with prolonged PFS
after panitumumab treatment [44]. This has led to the
approval of panitumumab for treatment of EGFR-positive,
metastatic colorectal carcinoma with disease progression
following chemotherapy [41]. As mentioned earlier, wild-
type KRAS is required for panitumumab eﬃcacy in patients
with mCRC [31].
The combination of EGFR- and VEGF-targeting anti-
bodies was also found to lack beneﬁt in the case of
panitumumab. In the Panitumumab Advanced Colorectal
Cancer Evaluation (PACCE) study, patients with untreated
mCRC were randomized to FOLFOX or FOLFIRI based
on investigator or patient choice. This combination was
given with panitumumab plus bevacizumab or bevacizumab
alone. The combination of FOLFOX/panitumumab/bevaci-
zumab resulted in higher mortality compared to FOL-
FOX/bevacizumab alone. The primary endpoint of median
PFS was also shorter in the panitumumab arm. Based on
the results of the interim analysis, the study was stopped
and panitumumab was discontinued in both the FOLFOX
and FOLFIRI arms [45]. Similar to cetuximab, this trial
with panitumumab argues against the combined use of these
agents with bevacizumab in mCRC.
2.5. Sorafenib. Sorafenib is a novel multikinase inhibitor
with antiangiogenic and proapoptotic activity targeting
EGFR as well as multiple kinases including Raﬀ/MAPK-
ERK kinase, VEGFR-2, VEGFR-3, and PDGFR-β [39]. It is
approved for use in the treatment of renal cell carcinoma
(RCC) and hepatocellular carcinoma (HCC).
RCC is characterized by the loss of the von hippel landau
(VHL) gene, which leads to dysregulation of the VEGFR,
PDGFR-β, transforming growth factor-alpha (TGF-) α,
EGFR, and Raf pathways promoting angiogenesis, lymphan-
giogenesis, tumor cell growth, and survival. Furthermore,
RCC frequently displays EGFR immunoreactivity. Membra-
nousand/orcytoplasmicEGFRimmunostaining inRCCwas
present in 123 of 132 (93%) primary and 49 of 53 (92%)
metastatic samples with extensive immunoreactivity present
in 83% of primary and 74% of metastatic tumors [46].
In previously treated patients with metastatic RCC, the
activity of sorafenib was demonstrated in two randomized
trials. In the largest of these studies, a randomized phase
III trial of metastatic cytokine refractory RCC, signiﬁ-
cant response and improvement in PFS was demonstrated
(Table 4). At ASCO 2007, a ﬁnal analysis of survival was
presented.Therewasnostatisticallysigniﬁcantimprovement
in OS; survival beneﬁt was likely obscured since one half of
the patients originally assigned to placebo had switched to
sorafenib [47].
EGFR is frequently expressed in human hepatoma cells;
in fact, EGF is one of the mitogens required for the growth
of hepatoma cells. At the ASCO meeting in 2007, data was
released showing the eﬃcacy of sorafenib in HCC. The
Sorafenib HCC Assessment Randomized Protocol (SHARP)
Trial was a large phase III double-blind placebo-controlled
study evaluating the eﬃcacy of sorafenib versus BSC in
patients with advanced HCC who had not received previous
chemotherapy. Patients receiving sorafenib had a three-
month median survival beneﬁt compared to placebo. Impor-
tantly, sorafenib was the ﬁrst active treatment that has been
proven to confer a survival beneﬁt and to show promise as a
standardtreatmentforadvancedHCC[48].Inanotherphase
III randomized trial of sorafenib in Asia-Paciﬁc patients with
HCC, results mirrored those of the SHARP trial. Despite
Asia-Paciﬁc patients having more advanced disease based
on the Eastern Cooperative Oncology Group performance
status (ECOG PS), a signiﬁcant OS advantage with sorafenib
was conﬁrmed [49]. A North American phase II randomized
trial of doxorubicin with sorafenib versus doxorubicin with
placebo in 96 Child-Pugh A patients was published in
abstract form and presented at the 2007 European Cancer
Organization Conference (ECCO). Median TTP was two
months longer in the combination arm, but did not reachJournal of Oncology 5
Table 3: Selected clinical trials of cetuximab. EGFR, e p i d e r m a lg r o w t hf a c t o rr e c e p t o r ;BSC, best supportive care; OS, overall survival;
PFS, progression free survival; ORR, overall response rate; mCRC, metastatic colorectal cancer; FOLFIRI, 5 Flourouracil/Folinic Acid and
Irinotecan; CapOx, capecitabine/oxaliplatin; SCC, squamous cell carcinoma; IHC, Immunohistochemistry; CR, complete response; PR,
partial response; FISH, ﬂuorescent in situ hybridization.
Malignancy Regimen Number of patients Results Comments
mCRC Cetuximab vs. BSC
[17]
572pts
IHC EGFR+ mCRC
Previously treated
with chemotherapy
Cetuximab:
PR (8%)
SD (31.4%)
BSC:
PR (0%)
SD (10.9%)
Cetuximab was associated
with a signiﬁcant
improvement in OS
(P<. 001)
Cetuximab: OS (6.1mo),
BSC: OS (4.6mo)
mCRC
Cetuximab,
Irinotecan vs.
Cetuximab
monotherapy [18]
329pts
mCRC with
progression after
Irinotecan-based
chemotherapy
Cetuximab,
Irinotecan:
ORR (22.9%)
Cetuximab:
ORR (10.8%)
No diﬀerence in OS Median
time to progression:
Cetuximab, Irinotecan
(4.1mo), Cetuximab
(1.5mo)
mCRC
Cetuximab,
Irinotecan vs.
Irinotecan [19]
1298pts
EGFR+ mCRC
Cetuximab,
Irinotecan:
ORR (16.4%)
PFS (4.0mo)
Cetuximab:
ORR (4.2%)
PFS (2.6mo)
No signiﬁcant diﬀerence in
OS, but large number of pts
receiving Irinotecan
eventually got cetuximab
mCRC FOLFIRI +/−
Cetuximab [20]
1,217pts
EGFR+ mCRC
First-line treatment
FOLFIRI +
Cetuximab:
PFS (8.9mo)
ORR (46.9%)
FOLFIRI alone:
PFS (8mo)
ORR (38.7%)
15% relative risk reduction
of progression
mCRC
CapOx,
bevacizumab +/−
Cetuximab [21]
775pts
Previously untreated
mCRC
CapOx,
bevacizumab:
ORR (40.6%)
PFS (10.7mo)
Cetuximab arm:
ORR (43.9%)
PFS (9.8mo)
Cetuximab combination
was worse in PFS
No diﬀerence in OS
mCRC FOLFOX +/−
Cetuximab [22]
337pts
134pts wild-type
KRAS
99pts mutant KRAS
Wild-type KRAS
response with
FOLFOX +
Cetuximab (ORR
61%, PFS 7.7mo)
Mutant KRAS
response with
FOLFOX +
Cetuximab (ORR
33%, PFS 5.5mo)
Cetuximab only beneﬁts
patients with wild-type
KRAS (HR 0.448,
P = .0009)
mCRC FOLFIRI +/−
Cetuximab [23]
1,217pts
348pts wild-type
KRAS
192pts mutant KRAS
Wild-type KRAS
response with
FOLFIRI +
Cetuximab (ORR
59%, PFS 9.9mo)
Mutant KRAS
response with
FOLFIRI +
Cetuximab (ORR
36%, PFS 7.6mo)
Cetuximab only beneﬁts
patients with wild-type
KRAS and reduced risk for
disease progression by 32%
(P = .017)6 Journal of Oncology
Table 3: Continued.
Malignancy Regimen Number of patients Results Comments
SCC of the Head and Neck
Platinum (cisplatin
or carboplatin),
ﬂuorouracil +/−
Cetuximab [25]
442pts
Untreated recurrent
or metastatic SCC of
the head and neck
Platinum,
ﬂuorouracil,
Cetuximab:
ORR (36%)
PFS (5.6mo)
Platinum,
ﬂuorouracil:
ORR (20%)
PFS (3.3mo)
Median OS was
signiﬁcantly improved in
the Cetuximab arm
(10.1mo vs. 7.4mo),
P = .04
SCC of the Head and Neck
Cisplatin,
Cetuximab vs.
Cisplatin [26]
117pts
Recurrent/metastatic
SCC of the head and
neck
Cisplatin,
Cetuximab:
ORR (26%)
Cisplatin
ORR (10%)
No signiﬁcant
improvement in OS or PFS
Enhanced response for
patients with EGFR
staining less than 80% by
IHC
SCC of the Head and Neck
Radiation,
Cetuximab vs.
Radiation alone
[27]
424pts
Locoregionally
advanced SCC of the
head and neck
Radiation,
Cetuximab:
PFS (17.1mo)
OS (49mo)
Radiation alone:
PFS (12.4mo)
OS (29.3mo)
OS beneﬁt favoring
Cetuximab arm (P = .03)
Incidence in grade 3 or
higher side eﬀects,
including mucositis, did
not diﬀer signiﬁcantly
between the groups
Pancreatic cancer
Cetuximab,
Gemcitabine vs.
Gemcitabine alone
[30]
735pts
Cetuximab,
Gemcitabine:
ORR (14%)
PFS (3.5mo)
OS (6.4mo)
Gemcitabine alone:
ORR (12%)
PFS (3mo)
OS (5.9mo)
The addition of Cetuximab
did not signiﬁcantly
improve ORR, PFS, or OS
NSCLC
Cisplatin,
Vinorelbine +/−
Cetuximab [31]
1,125pts
Only pts with EGFR
detected by IHC were
randomized
Cisplatin,
Vinorelbine,
Cetuximab:
Median OS
(11.3mo)
Cisplatin,
Vinorelbine:
Median OS
(10.1mo)
OS signiﬁcantly improved
in Cetuximab arm
(P = .04)
NSCLC
Sequential or
concurrent
carboplatin and
paclitaxel with
cetuximab [32]
229pts
EGFR by FISH
assessable in 76pts
(positive in 59%)
FISH-positive:
CR/PR (81%)
Median PFS (6mo)
FISH-negative:
CR/PR (55%)
Median PFS (3mo)
Median OS superior in
FISH-positive (15mo vs.
7mo),P = .04
statistical signiﬁcance. However, OS was signiﬁcantly longer
for the combination of sorafenib/doxorubicin compared to
the doxorubicin only arm (13.7 vs. 6.5mo) [50].
Sorafenib has also recently demonstrated signiﬁcant
activity in the treatment of iodine-refractory thyroid carci-
noma. In a phase II trial of 30 subjects, most of the patients
(80%) showed a clinical beneﬁt from this agent. Ninety-
ﬁve percent of individuals with available thyroglobulin levels
showed a rapid response in thyroglobulin levels with a mean
decreaseof70%.Theseresultsrepresentasigniﬁcantadvance
in both response and PFS over studies in the past utilizing
chemotherapy [51].
2.6. Sunitinib. Like sorafenib, sunitinib is an oral small
molecule TKI that inhibits cellular signaling by targeting
EGFR, VEGFR, PDGFR-β, fetal liver tyrosine kinase receptor
(FLT-3), and c-Kit, a stem cell factor receptor [52]. This
ultimately targets both angiogenesis and tumor cell prolif-
eration causing tumor shrinkage and cell death. Sunitinib
is currently approved for the treatment of RCC as wellJournal of Oncology 7
Table 4: Selected clinical trials of panitumumab. mCRC, metastatic colorectal cancer; BSC, best supportive care; OS, overall survival; PFS,
progression free survival; ORR, overall response rate; SD, stable disease; FOLFOX, 5 Flourouracil/Folinic Acid and oxaliplatin; FOLFIRI, 5
Flourouracil/Folinic Acid and Irinotecan.
Malignancy Regimen Number of patients Results Comments
mCRC Panitumumab vs. BSC
[35]
463pts
Pts with progression
after standard
chemotherapy
Panitumumab:
ORR (10%)
PFS (13.8 weeks)
BSC:
ORR (0%)
PFS (8.5 weeks)
No signiﬁcant
improvement in OS
mCRC
Panitumumab
monotherapy after
disease progression
with BSC [36]
176pts
Pts with progression
of disease in BSC arm
of Panitumumab vs.
BSC trial [35]
Panitumumab:
ORR (11.6%)
SD (33%)
Median PFS of 9.4
weeks
Results comparable to
initial study
mCRC
FOLFOX or FOLFIRI
with Bevacizumab +/−
Panitumumab [37]
823pts
FOLFOX,
Bevacizumab,
Panitumumab:
Median PFS (9.5mo)
OS (19.3mo)
FOLFOX,
Bevacizumab:
Median PFS (11mo)
OS (20.6mo)
Panitumumab in
combination with
FOLFOX and
bevacizumab was
associated with a
shorter PFS and
increased toxicity
as gastrointestinal stromal tumors GISTs. Like RCC, EGFR
expression in GISTs had been validated in a recent article in
which tissue microarray samples of 33 GISTs were surveyed
byIHC.EGFRexpressionwasidentiﬁedin8ofthosesamples
[53].
The antitumor activity of sunitinib was initially shown
in two phase II trials of metastatic RCC patients who had
failed previous cytokine therapy [54, 55]. This led to a large
phase III trial comparing sunitinib to interferon-alpha (IFN-
α) as ﬁrst-line therapy (Table 5). Sunitinib showed superior
activity in ORR and in PFS, including patients with good,
intermediate, and poor risk features. Furthermore, OS was
signiﬁcantly longer in the sunitinib arm, despite signiﬁcant
patient crossover from the IFN-α arm to sunitinib [56].
Sunitinib was also found to be superior in QOL compared
to IFN-α [57].
Sunitinibhasalsoshownsigniﬁcantactivityinmetastatic
and/or unresectable GIST following imatinib failure. In a
phase III randomized trial comparing sunitinib to placebo
in imatinib refractory GIST patients, time to tumor pro-
gression and PFS was 4-fold longer in patients on sunitinib
compared to placebo; partial response (PR) and stable
disease (SD) were also signiﬁcantly longer in the suni-
tinib arm. Patients in the placebo arm were subsequently
allowed to crossover to the Sunitinib arm if disease pro-
gression was documented during the study. The crossover
patient population yielded comparable results. Despite the
crossover, OS favored patients initially treated with sunitinib
[58].
2.7. Lapatinib. Activation and overexpression of oncogenes
encoding trans-membrane receptor tyrosine kinases of the
EGFR family, including EGFR (ErbB1) and HER2/neu
(ErbB2), play an important role in the development
of breast cancer [58]. Lapatinib is an orally active 4-
anilinoquinazoline TKI of both HER2/neu (ErbB2) and
EGFR (ErbB1). It inhibits the autophosphorylation sites on
the receptors, thereby blocking the downstream signaling
pathways of HER2 and EGFR.
Lapatinib has shown activity for the treatment of
advanced HER2/neu positive metastatic breast cancer refrac-
tory to trastuzumab (Table 6). Unlike trastuzumab, lapatinib
seems to have activity against brain metastases [59–61].
Primary and secondary resistances have been seen in patients
with HER2-positive breast cancers who had been treated
with trastuzumab both in the metastatic and adjuvant
settings [53, 62–65]. Potential mechanisms of resistance may
be related to signaling through other receptors such as EGFR
or IGFR-1 [66]. Lapatinib, being a small molecule TKI,
interacts with intercellular domains and does not require
full receptor activity. In a phase III study of HER2-positive
advanced or metastatic breast cancer refractory to anthracy-
clines, taxanes, and trastuzumab, lapatinib plus capecitabine
showed a signiﬁcant advantage over capecitabine monother-
apy with respect to ORR and PFS with a nonsigniﬁcant
trend toward longer OS [67]. In another phase III ran-
domized trial, the combination of paclitaxel with lapatinib
compared to paclitaxel monotherapy in patients with HER2-
positive cancer was evaluated. Patients in this trial were
not treated with prior trastuzumab. The study showed a
statistically signiﬁcant advantage in ORR and TTP, but
not in OS. Enrollment for this study came from countries
with limited HER2 testing. Only 91 of 580 patients were
HER2-positive on central testing, with retrospective analysis
revealing beneﬁt limited to FISH-positive or IHC 3+ tumors
[68].8 Journal of Oncology
Table 5: Selected clinical trials of sorafenib. PFS, progression free survival; OS, overall survival; PR, partial response; CR, complete response;
HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; TBRR, Tumor burden reduction rate.
Malignancy Regimen Number of patients Response rate Comments
RCC Sorafenib vs.
placebo [41]
903
Resistant to
standard therapy
Sorafenib:
Median PFS (5.5mo)
PR (10%)
Placebo:
Median PFS (2.8mo)
P<0.01
PR (2%)
The OS showed reduced risk
of death compared with
placebo but the results were
not statistically signiﬁcant
HCC Sorafenib vs.
placebo [42]
602pts
No previous
therapy
Sorafenib:
Median OS (10.7mo)
Placebo:
Median OS (7.9mo)
The median OS was
signiﬁcantly longer in patients
who received Sorafenib HR
(0.69), P = .0006
Metastatic thyroid
carcinoma
Sorafenib
monotherapy [45]
36pts
Metastatic,
iodine-refractory
thyroid carcinoma
PR in 7pts (21%)
SD in 20pts (59%)
Signiﬁcant anti-tumor activity
with overall clinical beneﬁt
rate (PR + SD) of 80%
Table 6: Selected clinical trials of sunitinib. GIST, gastrointestinal stromal tumor; PFS, progression free survival; OS, overall survival; PR,
partial response; CR, complete response; TTP, time to progression; mR C C , metastatic renal cell carcinoma; QOL, quality of life.
Malignancy Regimen Number of patients Response rate Comments
RCC Interferon vs.
Sunitinib [48]
750pts
Previously untreated
mRCC
Sunitinib:
Median PFS (11mo)
ORR (31%)
OS (26.4mo),
P = 0.051
Interferon:
Median PFS (5mo)
ORR (6%)
OS (21.8mo)
Sunitinib provides superior
QOL compared with IFN-α
in mRCC patients.
GIST Sunitinib vs.
placebo [50]
312pts
After progression or
intolerance to imatinib
Sunitinib:
TTP(6.3mo)
Placebo:
TTP(1.5 month)
Sunitinib signiﬁcantly
improved TTP with a 67%
reduced risk of progression.
3.Anti-EGFRAgent-AssociatedToxicity
EGFR is expressed on nearly all normal cells, particularly
those of epithelial origin such as skin, liver, and gastroin-
testinal tract, but not on hematopoietic cells [69]. As a
consequence, the most commonly encountered toxic eﬀects
from these agents are rash and diarrhea. Along with other
toxicities,recognitionandmanagementofassociatedadverse
eﬀects with anti-EGFR agents will result in improved clinical
outcomes, patient compliance, and QOL.
3.1. Skin Toxicity. When EGF was initially discovered, it was
named for its ability to increase growth and keratinization of
skin epithelium [69]. EGFR was found to be expressed in the
human skin within keratinocytes, the follicular epithelium,
sweat and sebaceous glands, and in capillaries of the dermis
[70–73].Forthisreason,themostcommontoxicityofEGFR-
targeted agents involves the skin and adnexal structures
resulting in a rash and less commonly nail toxicity.
EGFR is expressed on hair follicles and sebaceous glands
and the binding of this receptor by inhibitors leads to a
disruption in proliferation, resulting in an immunological
reaction with skin inﬂammation, folliculitis, and rash [72,
73]. The most commonly seen skin reaction with EFGR
inhibitors is a follicular acneiform eruption, also termed
acne-like rash or folliculitis. EGFR-associated rash diﬀers
from acne in that there are no comedones or blackheads. The
incidence of an acneiform-like skin rash has been reported
to occur in about 85% of cetuximab-treated patients [74,
75]. Symptoms typically appear within two weeks after
starting treatment. This is mainly located on the face (nose,
cheeks, nasolabial folds, chin, forehead, and in a perioral
distribution). Other locations include the shoulders and
upper part of the back and chest. The rash tends to improve
over time even with continued use and does resolve fully
after cessation of therapy. In 35% of patients, dry itchy
skin of the arms and legs can occur, which can potentially
become secondarily infected by Staphylococcus aureus or
Herpes simplex infection [76].
There have been numerous studies showing a direct
correlation between the severity of a rash with response and
OS. In fact, the greatest beneﬁt in survival of cetuximab-
treated patients is seen in those with a grade 3 rash [27,
75, 76]. The degree of skin toxicity has been classiﬁed byJournal of Oncology 9
Table 7: Selected clinical trials of lapatinib. MBC, metastatic breast cancer; PFS, progression free survival; OS, overall survival; TTP, time to
progression.
Malignancy Regimen Number of patients Response rate Comments
MBC Capecitibine +/−
Lapatinib [59]
324pts
HER2-positive MBC that had
progressed with chemotherapy
(anthracycline, a taxane, and
trastuzumab)
Capecitabine,
Lapatinib:
TTP (6.2mo)
ORR (24%)
Capecitabine
monotherapy:
TTP (4.3mo)
ORR (14%)
Non-signiﬁcant trend toward
improved OS favoring
lapatinib Fewer pts in the
lapatinib arm developed brain
metastases as the ﬁrst site of
progression (13 vs. 4%)
MBC
Lapatinib, Paclitaxel vs.
Paclitaxel monotherapy
[60]
580pts
55% received prior
chemotherapy or hormonal
therapy
No pts received prior
traztuzumab
Lapatinib,
Paclitaxel:
ORR (60%)
Median TTP
(8mo)
Paclitaxel
monotherapy:
ORR (36%)
Median TTP
(6mo)
Improved clinical outcome
was seen with the
combination without a
signiﬁcant change in side
eﬀect proﬁle
No diﬀerence in OS, but
majority of pts were not
properly tested for HER2
Table 8: Management of anti-EGFR-associated rash and common terminology criteria for adverse events v3.0 (CTCAE), National Cancer
Institute.
CTC Grade Rash Management
1 Macular or papular eruption or erythema
Asymptomatic
Topical antibiotic agents
(metronidazole, erythromycin, and
clindamycin lotion)
Corticosteroid cream if an extensive
inﬂammatory component exists
2 Macular or papular eruption or erythema
Symptomatic covering <50% of body
Anti-inﬂammatory oral antibiotics
(minocycline or doxycycline)
Corticosteroid cream if an extensive
inﬂammatory component exists
3 Macular or papular eruption or erythema
Symptomatic covering >50% of body
Anti-inﬂammatory oral antibiotics
(minocycline or doxycycline)
Oral corticosteroids EGFR therapy
should be held until the acute
inﬂammatory phase has resolved
4 Generalized exfoliative, ulcerative, or
bullouis dermatitis
Anti-inﬂammatory oral antibiotics
(minocycline or doxycycline)
Oral corticosteroids (Medrol-dose
pack) EGFR therapy should be held
until the acute inﬂammatory phase has
resolved
The National Cancer Institute Common Toxicity Criteria
version 3.0 (Table 7). Prospective trials are needed to further
investigate the correlation between anti-EGFR therapy and
rash to elucidate the validity and clinical implications of this
association.
Recommendations in the management of EGFR-
associated rash have been limited by the lack of clinical
trials evaluating rash therapies (Table 8). This has led
to treatment recommendations based on the clinical
experience of dermatologists and oncologists familiar with
EGFR-associated rash. In general, preventive measures
are essential and include avoidance of soaps, limiting
shower time, use of lukewarm water, and liberal use
of skin moisturizers and emollients. Beneﬁcial topical
treatment approaches for a grade 1 rash include the use
of antibiotic agents (metronidazole, erythromycin, and
clindamycin lotion) as well as local corticosteroid cream if
an extensive inﬂammatory component is present. For grade
2 reactions, anti-inﬂammatory oral antibiotics (minocycline
ordoxycycline)shouldbeusedsincesecondaryinfectionsare
common. In the event of a grade 3 rash, oral corticosteroids
and antibiotics should be utilized and EGFR-targeted
therapy should be held until the acute inﬂammatory phase
has resolved [77, 78].10 Journal of Oncology
Rash and hand-foot syndrome, characterized by redness,
ulceration, and dysesthesia of the palms and soles, are the
most common adverse events associated with sorafenib and
sunitinib. Hand-foot syndrome associated with these agents
occurs in 20–30% of patients, with less than 10% experienc-
ing grade 3 or higher toxicity. It rapidly resolves with drug
discontinuation and topical emollients and moisturizers are
used to prevent and diminish toxicity. Other associated
adverse events seen with sorafenib and sunitinib include
diarrhea, hypertension, fatigue, and hematologic cytopenias
[79, 80].
Anti-EGFR therapy can also result in nail toxicity, which
can occur in 10–15% of patients after 4–8 weeks of therapy.
It can progress into a paronychia like cracking reaction, a
painfulanddiﬃculttotreatsideeﬀect[74].Someindividuals
require several months for complete healing after cessation
of therapy [71]. Hair disorders are also commonly seen with
these agents. Since EGFR signaling plays a vital role in the
initiation of hair growth, interruption of EGFR signaling
can result in disorganized hair follicles leading to follicular
necrosis and alopecia [81, 82].
Nimotuzumab, which is marketed under the name of
BIOMAbegfr, is a recombinant humanized IgG1 mono-
clonal antibody targeting EGFR. It has been approved for
SCC of the head and neck and glioma in a number of
countries.Intheclinicaltrialsthusfar,nimotuzumabhasnot
been associated with skin toxicity. Further clinical trials in
diﬀerent cancers are currently ongoing [83].
3.2.GastrointestinalToxicity. Theuseoforalanti-EGFRTKIs
hasbeenfoundtobestronglyassociatedwithgastrointestinal
toxicities including diarrhea and hepatotoxicity. The patho-
physiology of anti-EGFR-induced diarrhea is thought to
result from excessive chloride secretion inducing a secretory
diarrhea [84]. In large randomized trials, oral TKIs erlotinib
and lapatinib have been found to cause diarrhea in 40–60%
of patients with approximately 10% experiencing grade 3
or 4 toxicity [11, 14]. The reported incidence of diarrhea
associated with sorafenib and sunitinib has been 20–40%
[79, 81]. Diarrhea induced by oral TKIs can be managed
by lowering the dose and rarely involves treatment inter-
ruption. Loperamide is a useful therapy decreasing intestinal
motility.
Hepatic toxicity with asymptomatic elevations of trans-
aminases and hyperbilirubinemia is commonly associated
with oral TKIs. The mechanism of action is thought to be
direct targeting of hepatocytes that overexpress EGFR with
potential induction of chronic hepatitis with active necrosis.
The overall incidence of hepatotoxicity with oral anti-EGFR
TKIs has been reported at around 10% (2% grade 2 or 3)
[11, 14, 79, 80]. These compounds can be continued with
mild hyperbilirubinemia and should be discontinued with
grade 3 or 4 toxicity. Concurrent TKIs and hepatotoxic drugs
should be used with caution.
3.3. Pulmonary Toxicity. Interstitial lung disease related to
geﬁtinib therapy has been well reported, with a worldwide
incidence estimated at 1% [85, 86]. In a small series
from Japan, the incidence of ILD in 112 patients receiving
geﬁtinib was estimated at 5.4% [87]. Four deaths occurred,
all being in current or former smokers, with pre-existing
pulmonary ﬁbrosis being a signiﬁcant risk factor. The
adverse pulmonary eﬀects of erlotinib are less well known,
but cases of fatal ILD have been reported [88, 89]. A
phase 3b trial has been initiated to examine the eﬃcacy
and safety of erlotinib in advanced NSCLC with disease
progression afterchemotherapy. From a total of 229 patients,
one (0.4%) interstitial lung disease-like event was reported
[90].
3.4. Cardiac Toxicity. Cardiac toxicity with anti-EGFR TKIs
has been reported. It is clear that cardiotoxicity with TKIs is
not a “class eﬀect,” since it does not occur with all known
agents. Sunitinib caused a decline in left ventricular ejection
fraction (LVEF) below 50% in 11% of the patients [91]. In a
phase III trial comparing sunitinib to IFN-α, 10% of patients
had declines in LVEF after a median duration treatment
of 6 months [56]. Sorafenib has induced acute coronary
syndromes, including myocardial infarction. In the RCC
study comparing sorafenib to placebo, 2.9% of sorafenib-
treated patients had a myocardial infarction, compared to
0.4% in placebo-treated patients [47]. The cardiac toxicity of
lapatinib was analyzed in 3.558 patients treated in 18 phase
I–III clinical trials; 598 received prior anthracyclines and 759
had been given trastuzumab in the past [92]. Lapatinib was
associated with a decline in LVEF in 1.6% of patients (58 of
3,558). The mean LVEF decrease was 18.7% and was mostly
asymptomatic(1.4%asymptomaticand0.2%symptomatic).
OfthesevenwithsymptomaticLVEFdecrease,cardiotoxicity
resolved in all but one patient.
3.5. Allergic Reactions. Allergic and anaphylactoid reactions
are associated with cetuximab and, less often, panitumumab
administration [26, 75]. Severe reactions are observed in
approximately 3% of patients following cetuximab admin-
istration, with a fatal outcome in 0.1% of patients [93, 94].
Up to 90% of severe reactions associated with cetuximab
occur within the ﬁrst few minutes of the ﬁrst dose [95].
The decision to rechallenge or discontinue treatment after
a reaction occurs depends on the severity of the reaction.
In the case of anaphylactic reactions, further therapy with
cetuximab is contraindicated. Mild-to-moderate hypersensi-
tivity reactions can be managed by temporary infusion inter-
ruption and resuming at a slower infusion rate. Management
of severe reactions must include immediate interruption and
treatmentwith epinephrine. Corticosteroids, antihistamines,
bronchodilators, and oxygen also might be required.
Hypersentivity reactions to cetuximab might correlate
with the development of speciﬁc antihuman IgE antibodies
[96]. On the contrary, no antihuman antibodies have been
detected with panitumumab. The incidence of hypersen-
sitivity reactions with panitumumab in multiple trials has
been approximately 3%, with severe reactions accounting for
approximately 1% [97]. The successful use of panitumumab
after severe hypersensitivity reactions to cetuximab has been
reported, but requires further investigation [98].Journal of Oncology 11
4. Conclusions
Therapeutic agents in clinical practice targeting the EGFR
pathway have made great advances in the treatment of
malignancy.EGFRactivationisassociatedwithproliferation,
antiapoptosis, and metastatic spread, making this pathway
a compelling target. Numerous large clinical trials have
shown clinical evidence of anticancer activity with these new
agents resulting in improved tumor response and patients’
survival. Several other anti-EGFR agents are in development,
giving hope to future advances in therapy. An awareness
and proper management of associated toxicities can increase
patient compliance, QOL, and overall treatment success.
Ongoing and future research will expand the applications
of anti-EGFR therapy, elucidate optimal combinations and
sequences, discover pathways of resistance, and continue to
beneﬁt cancer patients.
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